ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
February 24 2017 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced it will report
financial results for the fourth quarter and full year 2016 before
the market opens on Tuesday, March 7, 2017. The Company will hold a
conference call and webcast on the same day at 9:00 a.m. ET to
discuss these results and provide a general business update.
The live webcast can be accessed in the “Investors & Media”
section of our website, www.arqule.com, under “Events &
Presentations." You may also listen to the call by dialing (877)
868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call
and can be accessed in the “Investors & Media” section of our
website, www.arqule.com, under “Events and Presentations."
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. Our mission is to discover, develop and commercialize
novel small molecule drugs in areas of high unmet need that will
dramatically extend and improve the lives of our patients. Our
clinical-stage pipeline consists of five drug candidates, all of
which are in targeted, biomarker-defined patient populations,
making ArQule a leader among companies our size in precision
medicine. ArQule’s most advanced product, in phase 3 clinical
development, is tivantinib (ARQ 197), an oral, selective inhibitor
of the c-MET receptor tyrosine kinase, for second-line treatment of
MET-overexpressing hepatocellular carcinoma in partnership with
Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule’s
proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for
multiple oncology indications; ARQ 092, a selective inhibitor of
the AKT serine/threonine kinase, in phase 1 for multiple oncology
indications as well as ultra-rare Proteus syndrome, in partnership
with the National Institutes of Health (NIH); ARQ 751, a next
generation AKT inhibitor, in phase 1 for patients with AKT1 and
PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated
as a promoter of NQO1-mediated programmed cancer cell necrosis, in
phase 1/2 in multiple oncology indications in partnership with the
University of Texas Southwestern Medical Center. In addition, we
have advanced ARQ 531, an investigational, orally bioavailable,
potent and reversible inhibitor of both wild type and C481S-mutant
BTK, through toxicology testing and plan to file an Investigational
New Drug Application in early 2017. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds. You can follow us on Twitter and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170224005008/en/
ArQule, Inc.Dawn Schottlandt, 781-994-0300Sr. Director, Investor
Relations/ Corp. Communicationswww.arqule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024